Chlorhexidine is named as an intervention in 3 current clinical trials in our China, USA and India registers. 2 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Janssen Research & Development, LLC (1). The most-studied condition is Carcinoma, Non-Small-Cell Lung.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Topical Chlorhexidine Spray for the Prevention of Acute Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma:
NCT07559877 · ClinicalTrials.gov ↗ · Nasopharangeal Cancer
|
Phase 3 | Recruiting | Jiangxi Provincial Cancer Hospital | China |
|
Evaluation of 2%Bromelain Gel With 0.2%CHX Gel as Subgingival LDD Following SRP in Stage II/III and Grade B Periodontitis -A RCT
NCT06505759 · ClinicalTrials.gov ↗ · Periodontal Pocket
|
Phase 1 | Recruiting | Krishnadevaraya College of Dental Sciences & Hospital | India |
|
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
NCT06120140 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung
|
Phase 2 | Active, closed | Janssen Research & Development, LLC | USA, China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
1 single-substance product containing Chlorhexidine on the HPRA medicines list.
No entry for Chlorhexidine in the EMA, FDA or German BfArM shortage lists we track.
| Lead sponsor | Trials |
|---|---|
| Janssen Research & Development, LLC | 1 |
| Krishnadevaraya College of Dental Sciences & Hospital | 1 |
| Jiangxi Provincial Cancer Hospital | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
| Clinical trials in USA | 1 | 0 |
| Clinical trials in India | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our China, USA and India registers name Chlorhexidine as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 3 trials are recruiting: 1 with sites in China and 1 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Janssen Research & Development, LLC (1), Krishnadevaraya College of Dental Sciences & Hospital (1) and Jiangxi Provincial Cancer Hospital (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 1 single-substance product containing Chlorhexidine, for example Chlorhexidine Acetate BP 0.05% w/v Irrigation solution (Baxter Holding B.V.). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Chlorhexidine has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Chlorhexidine works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Chlorhexidine works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Chlorhexidine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.